Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer.

Provided herein are novel 2,7-naphthyridine compounds as MASTL inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer.

Provided herein are novel KRAS inhibitors, pharmaceutical compositions, use of such compounds in treating non-small-cell lung cancer, and processes for preparing such compounds.

Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.

Provided herein are novel tyrosine kinase 2 inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune and inflammatory diseases, and processes for preparing such compounds.

Imidazopyridine Compounds as ERK5 Inhibitors for Treating Cancer.

Provided herein are novel imidazopyridine compounds as ERK5 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.

Provided herein are novel heteroaryl compounds as CD73 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Novel Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases.

Provided herein are novel compounds as S1P5 modulators, pharmaceutical compositions, use of such compounds in treating neurodegenerative diseases, particularly Alzheimer's disease, multiple sclerosis, migraine and amyotrophic lateral sclerosis, and processes for preparing such compounds.

Novel Furopyridine and Furopyrimidine Compounds as PI4K Inhibitors for Treating Malaria and Viral Infection.

Provided herein are novel furopyridine and furopyrimidine compounds as PI4K inhibitors, pharmaceutical compositions, use of such compounds in treating malaria and viral infections, and processes for preparing such compounds.

Novel HSD17B13 Inhibitors for Treating Liver Diseases.

Provided herein are novel HSD17B13 inhibitors, pharmaceutical compositions, use of such compounds in treating liver diseases, and processes for preparing such compounds.

Novel Myeloperoxidase Inhibitors for Treating Multiple Diseases.

Provided herein are novel myeloperoxidase inhibitors, pharmaceutical compositions, use of such compounds in treating inflammatory, cardiovascular, respiratory, renal, hepatic, and neurological diseases, cancer, and neutrophilic-driven diseases, and processes for preparing such compounds.

Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases.

Provided herein are novel pyrrolidinone derivatives as NIK inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune and inflammatory diseases, and processes for preparing such compounds.

Novel Exatecan-Derived Topoisomerase-1 Inhibitors for Treating Cancer.

Provided herein are novel exatecan-derived topoisomerase-1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Novel CD73 Inhibitors for Treating Cancer.

Provided herein are novel CD73 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Novel Phosphorylpurinone Compounds for Treating Cancer.

Provided herein are novel phosphorylpurinone compounds as TLR7 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases.

Provided herein are novel PCSK9 inhibitors, pharmaceutical compositions, use of such compounds in treating cardiovascular diseases, and processes for preparing such compounds.

Novel ACC Inhibitors for Treating Acne.

Provided herein are novel ACC inhibitors, pharmaceutical compositions, use of such compounds in treating acne, and processes for preparing such compounds.

Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis.

Provided herein are novel isoxazolidines as RIPK1 inhibitors, pharmaceutical compositions, use of such compounds in treating Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), and processes for preparing such compounds.

Novel Heterocyclic Compounds for Treating Huntington's Disease.

Provided herein are novel heterocyclic compounds, pharmaceutical compositions, use of such compounds in treating Huntington's disease, and processes for preparing such compounds.

Novel AT2R Antagonists for Treating Chronic Pain.

Provided herein are novel AT2R antagonists, pharmaceutical compositions, use of such compounds in treating chronic pain, and processes for preparing such compounds.

Novel Tetrahydropyrido[3,4-d]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases.

Provided herein are novel tetrahydropyrido[3,4-d]pyrimidines as HPK1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, inflammatory, and autoimmune diseases, and processes for preparing such compounds.

TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.

Provided herein are novel TYK2 inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune and inflammatory diseases, and processes for preparing such compounds.